The Homeland Security Digital Library (HSDL) maintains a collection of the Centers for Disease Control’s (CDC) Morbidity and Mortality Weekly Report (MMWR), which collects and analyzes data from the United States Department of Health and Human Services (HHS) on epidemiology and public health. Each issue of the MMWR is packed with raw and analyzed public health data and scientific studies from some of the top minds in the United States. Below we highlight some of the most current and informative studies included in their weekly reports.
Here are some important articles you may have missed from Volume 71, Issues 46-49 of the Centers for Disease Control’s Morbidity and Mortality Weekly Report (MMWR) Series.
December 9, 2022 / No. 49 Featured Articles:
This report discusses the case of a 7-year-old child in Texas who was bitten by a bat and later developed symptoms of rabies and succumbed to the disease. Although the child reported the incident to his parents, because he had no visible bite marks, no medical care was sought until 2 months later, when symptoms began. Unfortunately, once symptoms set in, rabies is almost always fatal. The report notes the need for more public education about seeking early treatment of postexposure prophylaxis (PEP) to prevent unnecessary deaths.
In this study, the Vaccine Adverse Event Reporting System (VAERS) data for the Monkeypox JYNNEOS Vaccine is analyzed. From May 22 through October 21, 2022, almost one million doses of the vaccine were administered. Out of 1,350 VAERS reports, 47% were administration errors, of which 98% did not report any adverse health event. 14 (1%) of reports were considered serious.
December 2, 2022 / No. 48 Featured Articles:
A preliminary analysis of the administration of Paxlovid (Nirmatrelvir-ritonavir) for people with symptomatic COVID-19 infections during April-September shows that use reduced hospitalizations by 51%. Its use is recommended in higher risk populations such as immunocompromised adults and adults 65 years of age or older, regardless of vaccination status.
This study reviews vaccine effectiveness (VE) of Bivalent mRNA vaccines from September through November 2022 using data received from the Increasing Community Access to Testing (ICATT) national SARS-CoV-2 testing program. The data implies that Bivalent mRNA vaccines were effective in providing “significant additional protection against symptomatic SARS-CoV-2 infection in persons who had previously received 2, 3, or 4 monovalent vaccine doses.”
November 25, 2022 / No. 47 Featured Article:
This report updates an earlier report regarding progress toward worldwide measles elimination. The goal of the World Health Organization (WHO) is a vaccination rate of “95% coverage needed to achieve and sustain measles elimination.” To date, this goal has never been achieved in any WHO region. A peak of 86% worldwide overall was reached in 2019, but due to pandemic interruptions, those levels decreased to “83% in 2020 and to 81% in 2021.” Further data on disruptive measles outbreaks is provided.
November 18, 2022 / No. 46 Featured Article:
PRIORIX is a newer vaccine against Measles, Mumps and Rubella, released in June 2022. It is considered interchangeable with the Merck and Co., Inc.’s M-M-R II vaccine that has been in use since 1978. This report provides key findings, clinical guidance, and precautions/contraindications.
For more information on COVID, visit HSDL’s COVID-19 Resource Archive. You can also find pandemic-related resources in HSDL’s In Focus on Pandemics and Epidemics, and search our statistical resources related to public health.